Therapeutic peptide and biomarkers for castration-resistant prostate cancer (CRPC) Synthetic peptide targeting PRAC1 has been developed for the treatment of CRPC. Prostate cancer is an androgen dependent tumor, and the androgen receptor (AR) drives numerous mechanisms involved in disease progression. The standard therapy for metastatic PC involves various pharmacological approaches that inhibit the AR signaling axis. Despite initial profound responses to androgen deprivation therapies, most patients progress to castration-resistant prostate cancer (CRPC). Highly potent second-generation AR signaling inhibitors (ARSI), such as abiraterone acetate and enzalutamide, that were developed to overcome this resistance have shown improvements in outcomes, but essentially all patients develop resistance to these agents. Much of the mortality associated with advanced PC can be attributed to resistance to ARSI. Dr. Michael Haffner and his collaborator have identified PRAC1 as a novel intra-cellular target that could be exploited for the treatment of prostate cancer. Additionally, synthetic peptide targeting PRAC1 has been developed for the treatment of castration-resistant prostate cancer (CRPC). PRAC1 could also be used as a biomarker to predict treatment outcome. <ul> <li>Biomarker to predict treatment outcome for hormonal therapy</li> <li>Synthetic PRAC1 peptide as a therapeutic candidate for CRPC</li> </ul> <ul> <li>Synthetic PRAC1 peptide is optimized to be cell penetrable</li> <li>In vivo studies in xenograft models show tumor suppression</li>
</ul> <ul> <li>Michael C. Haffner, MD, PhD - Assistant Professor, Human Biology Division, Clinical Research Division</li> </ul> Preclinical in vivo data available Provisional Patent Application Filed 23205HaffnerPRAC1.pdf PRAC1 | prostate cancer | breast cancer | Haffner | CRPC | peptide Haffner-prac1-prostate-cancer